A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)

Inclusion Criteria: * Have a diagnosis of RA for at least 3 months prior to screening * Have no history of latent or active tuberculosis (TB) and test negative for TB Exclusion Criteria: * Have inflammatory diseases other than RA * Have been treated with disease-modifying anti-rheumatic drugs (DMARDs)/systemic immunosuppressives other than methotrexate (MTX), sulfasalazine, or hydroxychloroquine during the 4 weeks prior to the first administration of study agent * Have received intramuscular (IM), IV, or intra-articular corticosteroids within 4 weeks of study agent administration * Have a known hypersensitivity to human Ig proteins * Have received infliximab, golimumab, adalimumab or abatacept within 3 months, or etanercept or anakinra within 1 month prior to the first administration of study agent * Have received alefacept, efalizumab, natalizumab, rituximab, or any B-cell-depleting agent * Have been treated with any other biologics or investigational drugs, within 5 half-lives of that drug prior to the first administration of study agent * Have a history of latent or active granulomatous infection, including tuberculosis (TB), histoplasmosis, or coccidioidomycosis, prior to screening * Have had a Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening * Have had a serious infection (eg, hepatitis, pneumonia, pyelonephritis, or sepsis)